Literature DB >> 26202497

Interferon graft dysfunction: a final chapter for interferon and hepatitis C.

Julie A Thompson1, John R Lake2.   

Abstract

Entities:  

Year:  2014        PMID： 26202497     DOI： 10.1007/s12072-014-9535-7

Source DB:  PubMed          Journal:  Hepatol Int        ISSN： 1936-0533            Impact factor:   6.047


× No keyword cloud information.
  11 in total

1.  Virus interference. I. The interferon.

Authors:  A ISAACS; J LINDENMANN
Journal:  Proc R Soc Lond B Biol Sci       Date:  1957-09-12

2.  Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon.

Authors:  Josh Levitsky; Maria Isabel Fiel; John P Norvell; Edward Wang; Kymberly D Watt; Michael P Curry; Sumeet Tewani; Timothy M McCashland; Maarouf A Hoteit; Abraham Shaked; Samuel Saab; Amanda C Chi; Amy Tien; Thomas D Schiano
Journal:  Gastroenterology       Date:  2012-01-25       Impact factor: 22.682

Review 3.  A practical guide to the management of HCV infection following liver transplantation.

Authors:  K Watt; B Veldt; M Charlton
Journal:  Am J Transplant       Date:  2009-06-16       Impact factor: 8.086

Review 4.  Banff schema for grading liver allograft rejection: an international consensus document.

Authors: 
Journal:  Hepatology       Date:  1997-03       Impact factor: 17.425

5.  Patterns of recurrent hepatitis C after liver transplantation in a recent cohort of patients.

Authors:  Urmila Khettry; Weei-Yuan Huang; Mary Ann Simpson; Elizabeth A Pomfret; James J Pomposelli; W David Lewis; Roger L Jenkins; Fredric D Gordon
Journal:  Hum Pathol       Date:  2006-12-22       Impact factor: 3.466

6.  Latent autoimmune thyroiditis in untreated patients with HCV chronic hepatitis: a case-control study.

Authors:  N Ganne-Carrie; A Medini; E Coderc; O Seror; C Christidis; S Grimbert; J C Trinchet; M Beaugrand
Journal:  J Autoimmun       Date:  2000-03       Impact factor: 7.094

7.  Strategies to treat interferon-induced graft dysfunction after living donor liver transplantation for hepatitis C.

Authors:  Toru Ikegami; Huanlin Wang; Tomoharu Yoshizumi; Takeo Toshima; Shinichi Aishima; Takasuke Fukuhara; Norihiro Furusyo; Kazuhiro Kotoh; Shinji Shimoda; Ken Shirabe; Yoshihiko Maehara
Journal:  Hepatol Int       Date:  2013-12-27       Impact factor: 6.047

8.  Hepatitis C-related posttransplant plasma cell proliferative disorder with hepatitis C virus in neoplastic plasma cells: a new posttransplant disease entity?

Authors:  H W Tun; M Krishna; D M Menke
Journal:  Transplant Proc       Date:  2004-11       Impact factor: 1.066

9.  Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus.

Authors:  M Isabel Fiel; Kaushik Agarwal; Carmen Stanca; Nassim Elhajj; Nikolas Kontorinis; Swan N Thung; Thomas D Schiano
Journal:  Liver Transpl       Date:  2008-06       Impact factor: 5.799

10.  Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot study of efficacy and safety.

Authors:  Steven K Herrine; Robert S Brown; David E Bernstein; Michael S Ondovik; Ellen Lentz; Helen Te
Journal:  Dig Dis Sci       Date:  2005-04       Impact factor: 3.487
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.